Evidence map›Paper›PMID 34227914›Full record

ArticleHuman vaccines & immunotherapeutics2022

COVID-19 vaccine hesitancy in Zambia: a glimpse at the possible challenges ahead for COVID-19 vaccination rollout in sub-Saharan Africa.

Andrea C Carcelen, Christine Prosperi, Simon Mutembo, Gershom Chongwe, Francis D Mwansa, Phillimon Ndubani, Edgar Simulundu, Innocent Chilumba, Gloria Musukwa, Phil Thuma and 6 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Correlates of COVID-19 vaccine uptake among the forcibly displaced: evidence from Libya.Archives of public health = Archives belges de sante publique · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Andrea C CarcelenDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Christine ProsperiDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Simon MutemboDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0002-5389-5966
Gershom ChongweDepartment of Immunology, Tropical Diseases Research Center, Ndola, Zambia.ORCID 0000-0003-3303-308X
Francis D MwansaMinistry of the Health, Government of the Republic of Zambia, Lusaka, Zambia.
Phillimon NdubaniLaboratory Science, Macha Research Trust, Choma, Zambia.
Edgar SimulunduLaboratory Science, Macha Research Trust, Choma, Zambia.
Innocent ChilumbaDepartment of Immunology, Tropical Diseases Research Center, Ndola, Zambia.
Gloria MusukwaLaboratory Science, Macha Research Trust, Choma, Zambia.
Phil ThumaLaboratory Science, Macha Research Trust, Choma, Zambia.
Kelvin KapunguDepartment of Immunology, Tropical Diseases Research Center, Ndola, Zambia.
Mutinta HamahuwaLaboratory Science, Macha Research Trust, Choma, Zambia.
Irene MutaleDepartment of Immunology, Tropical Diseases Research Center, Ndola, Zambia.
Amy WinterDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
William J MossDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0001-6579-3513
Shaun A TrueloveDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0003-0538-0607

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With unprecedented speed, multiple vaccines against SARS-CoV-2 are available 1 year after the COVID-19 pandemic was first identified. As we push to achieve global control through these new vaccines, old challenges present themselves, including cold-chain storage, the logistics of mass vaccination, and vaccine hesitancy. Understanding how much hesitancy toward COVID-19 vaccines might occur and what factors may be driving these concerns can improve the ability of public health workers and communicators to maximize vaccine uptake. We nested a survey within a measles-rubella mass vaccination campaign in Zambia in November 2020 and asked about sentiments and beliefs toward COVID-19 and COVID-19 vaccines. Among parents bringing their children to receive a measles-rubella vaccine, we found high acceptability of COVID-19 vaccination of their children, but substantial uncertainty and hesitancy about receiving the vaccine themselves. COVID-19 vaccination hesitancy was correlated with beliefs around COVID-19 severity and risk, as well as vaccine safety and effectiveness.

Indexed as

COVID-19VaccinesChildCOVID-19 VaccinesHumansMass VaccinationMeasles VaccinePandemicsSARS-CoV-2VaccinationVaccination HesitancyZambiaCOVID-19 VaccinesMeasles VaccineVaccinesCOVID-19vaccinevaccine acceptancevaccine hesitancyvaccine safetyZambia

Identifiers

PMID34227914
PMCPMC8920139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.